Address drug resistant pathogens as part of 'next stage of global health'

This post in the Foreign Policy Association blog discusses reports from earlier this month of "an emerging strain of 'totally drug-resistant' tuberculosis (TDR-TB)" in India, which the Indian government last week denied, "arguing that the 12 cases were in fact extensively drug resistant (XDR)." The blog states, "Whether or not it's fair to use the TDR moniker, drug resistance is a serious, emerging issue that may very well define the next stage of global health," concluding, "We are reaching a turning point, one at which some drug resistant pathogens are on the cusp of shifting from a handful of cases, an endemic, to a bigger, epidemic or even pandemic problem. Now is the time to initiate discussions on what the global community will do to stem drug resistance" (Robinson, 1/21).

Print


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024